Charles River Announces First-Quarter 2008 Results
Downloadable version.
- First-Quarter Sales Increase 16% to $338 Million Due to Strong Customer Demand
- First-Quarter GAAP EPS of $0.64 and Non-GAAP EPS of $0.72
- Reaffirms Guidance for 2008
WILMINGTON, Mass., May 06, 2008 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2008. For the quarter, net sales increased 16.0% to $337.7 million from $291.2 million in the first quarter of 2007. Both the Research Models and Services (RMS) and Preclinical Services (PCS) business segments reported strong sales growth, driven by demand for our broad portfolio of essential drug discovery and development products and services, as pharmaceutical and biotechnology companies invested in basic research and increased their strategic use of outsourced drug development services. Foreign exchange contributed 4.2% to the net sales growth.
Click here to read the full release.